medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2003, Number 1

<< Back Next >>

Acta Med 2003; 1 (1)

Effect of Hormone Replacement Therapy on Bone Remodeling Biochemical Markers and Somatotropic Axis during Postmenopause

Ángeles L, Hernández-Valencia M, Ochoa R, Saucedo R, Zárate A

Language: Spanish
References: 15
Page: 17-21
PDF size: 84.87 Kb.


ABSTRACT

Somatotropic axis in menopausal women experiences variations that can influence changes in bone metabolism. Therefore, we carried out this study in postmenopausal women from 50-62 years of age to know variations of biochemical bone remodeling markers and correlation with somatotropic axis. Osteocalcin levels were measured, as well as deoxypyridinoline, bone-specific alkaline phosphatase, GH, and IGF-I, in addition to 17-Β estradiol (E2) and FSH by chemoluminescent methods and radioimmunoassays. There were correlations between osteocalcin (r = -0.64, p ‹ 0.01) and bone-specific alkaline phosphatase (r = ‹ 0.05) with E2, respectively; we observed that when E2 decreased, concentration of these two bone modeling markers increased. There also was correlation (p ‹ 0.05) between GH and osteocalcin, which could be best indicator in bone formation compared with bone-specific alkaline phosphatase. In addition, it was demonstrated that GH and IGH-I with low concentration in postmenopausal women contribute with negative changes in bone metabolism; therefore, somatotropic axis can be used as risk index in patients with bias for osteoporosis.


REFERENCES

  1. Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-650.

  2. Cosman F, Nieves J, Wilkinson C, Schnering D, Shen V, Lindsay R. Bone density changes and biochemical indices of skeletal turnover. Calcif Tissue Int 1996; 58: 236-243.

  3. Peterlik M. Aging, neuroendocrine function, and osteoporosis. Exp Gerontol 1997; 32: 577-586.

  4. Peienl P, Griesmacher A, Pointinger P, Marteau R, Hartl W, Gruber W, Bröll H. Association between female sex hormone and biochemical markers of bone turnover in peri-and postmenopausal women. Calcif Tissue Int 1998; 62: 388-394.

  5. Akesson K, Vergnaud P, Gineyts E. Impairment of bone in elderly women with hip fracture. Calcif Tissue Int 1993; 53: 162-169.

  6. Mundy RG. Cellular and molecular regulation of bone turnover. Bone 1999; 24: 35-38.

  7. Raisz GL. Physiology and pathophysiology of bone remodeling. Clin Chem 1999; 45: 1353-1358.

  8. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis-second decade. Endocrinology 1998; 139: 2659-2661.

  9. Fonseca ME, Ochoa R, Galván RE, Hemández M, Mercado M, Zárate A. Increased serum levels of growth hormone and insulin-like growth factor-1 associated with simultaneous decreased circulating insulin in postmenopausal women receiving hormone replacement therapy. Menopause 1998; 6: 56-60.

  10. Canalis E, Agnus D. Insulin-like factors and their role in osteoporosis. Calcif Tissue Int 1996; 58: 133-134.

  11. Stepan JJ. Prediction of bone loss in postmenopausal women. Osteoporos Int 2000; Suppl 6: S45-S54.

  12. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999; 45: 1359-1368.

  13. Robins SP. Crosslinking of collagen: isolation structural characterization and glycosylation of pyridinoline. Biochem J 1983; 215: 167-173.

  14. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzymelinked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994; 10: 1643-1649.

  15. Heaney RP, Abrams SA, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, Weaver C. Peak bone mass. Osteoporos Int 2000; 11: 985-1009.




2020     |     www.medigraphic.com